炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 出品：新浪财经上市公司研究院 作者：天利 | | 截至12月31日 | 截至9月30日 | | --- | --- | --- | | | 2024年 | 2025年 | | | (人民幣千元) | | | | | (未經濟計) | | 非流動資產 | | | | 物業、廠房及設備 | 1.605 | 1.026 | | 使用權資產 ... | | 9,048 | | 無形資産 . | 269 | 217 | | 預付款項、按金及其他應收款項 | 277 | 680 | | 非流動資產總值 | 2,151 | 10,971 | | 流動資產 | | | | 存貸 | 8.928 | 13.095 | | 預付款項、按金及其他應收款項 | 13.907 | 5.326 | | 以公允價值計量且其變動計入當期損益的金融資產 | 89.074 | 151.932 | | 定期存款 | 3.954 | 4.107 | | 現金及現金等價物 | 10.063 | 117.957 | | 流動資產總值 | 125,926 | 292,417 | 晚 ...

Group 1 - Seasonal influenza impacts approximately 1 billion people globally each year, with 3 to 5 million cases developing into severe illness and 290,000 to 650,000 deaths due to influenza-related respiratory diseases [1] - The domestic influenza treatment drug market is currently dominated by Dongyangguang Pharmaceutical with Oseltamivir, but new players are rapidly emerging since 2025 [1] - Zhengxiang Pharmaceutical is seeking to list on the Hong Kong Stock Exchange, having submitted its application on January 30, with CICC as its sole sponsor [2][4] Group 2 - Zhengxiang Pharmaceutical's antiviral drug, Marcilosavir, has already been approved for market release, distinguishing it from most other 18A companies [3] - The company was founded in 2018 and has undergone multiple rounds of financing, raising a total of 872 million RMB, with a post-investment valuation of 2.48 billion RMB as of January 2026 [4][5] - The company has a drug portfolio that includes six assets, with Marcilosavir being the core product, which is a new generation antiviral targeting influenza [10][12] Group 3 - The global market for influenza treatment and prevention drugs is projected to reach $4.8 billion by 2024, with China contributing $1.7 billion [16] - The Chinese market for antiviral drugs is expected to grow to 13.6 billion RMB by 2035, with PA inhibitors and other antiviral drugs accounting for 13 billion RMB [17] - Marcilosavir faces competition from several established products, including Roche's Baloxavir and others, with pricing set at 222 RMB per box, which is higher than some competitors [20] Group 4 - Zhengxiang Pharmaceutical reported zero revenue for 2024 and 400,000 RMB for the first nine months of 2025, primarily from regulatory support services for Marcilosavir [23] - The company incurred losses of approximately 145 million RMB for both 2024 and the first nine months of 2025, totaling around 290 million RMB in cumulative losses [23] - The company collaborates with a national CSO, Jichuan Pharmaceutical, to enhance market share through its established distribution network [24] Group 5 - The company has a total of 52 R&D personnel, with significant expenditures on drug development, amounting to 100 million RMB and 81.6 million RMB in R&D costs for the respective reporting periods [23] - As of November 2025, the company had cash and cash equivalents of 523 million RMB and term deposits of 141 million RMB [27] - The overall cash flow from operating activities showed a net outflow of 1.06 billion RMB for 2024, indicating financial challenges [28]

征祥医药收入高度依赖去年7月获批的流感新药玛硒洛沙韦片，但目前该产品尚未贡献主要收入。其面 临的市场竞争激烈——青峰药业、众生药业的流感药物已先一步获批并进入医保，健康元药业的相关产 品也于去年12月获批。作为后来者，征祥医药亟须突出市场重围。在此背景下，赴港上市成为征祥医药 缓解债务压力、为后续发展寻求资金支持的关键步骤。 背负巨债的征祥医药（南京）集团有限公司（以下简称"征祥医药"），正将其未来押注于一款流感新 药，并由此启动港股上市进程。近日，征祥医药向港交所递交招股书，拟港股上市。招股书显示，2024 年及2025年前三季度，征祥医药营收合计不足40万元，同期亏损累计近3亿元，经营活动现金流持续为 负。截至2025年9月末，负债净额攀升至9.56亿元，资产负债率达415.84%。 在定价策略上，玛硒洛沙韦片的定价与罗氏的玛巴洛沙韦一致，均为222元/盒。相比之下，同为PA抑制 剂的青峰药业的玛舒拉沙韦片和健康元药业的玛帕西沙韦定价分别为175元和198元。征祥医药的产品在 性价比方面并不占优势。 不仅如此，根据京东平台流行性感冒用药排行榜数据，玛巴洛沙韦及磷酸奥司他韦依然占据销量的绝对 主导地位。而在 ...

"孩子上月确诊流感，吃了玛巴洛沙韦很快好转，但网上总说病毒会变异耐药，下次再得流感这药还管 用吗？"市民李女士的困惑，反映出不少家庭对于流感用药的普遍顾虑。 日前，复旦大学附属华山医院感染科张文宏教授团队发布的中国首个玛巴洛沙韦耐药性真实世界监测研 究成果，恰好为这类疑问给出了科学答案。 耐药突变发生率极低 该研究对近4000例中国人群（含44.6%儿童）样本开展系统分析，证实玛巴洛沙韦耐药突变发生率极低 （＜0.05%）。在三个流感流行季广泛使用后，我国大陆未检测出国际标志性I38X耐药突变，这与中国 疾控中心流感周报中该药物耐药率为"0"的监测结果形成呼应。 只有掌握自身基线数据，流感防控策略才能更精准。张文宏介绍，玛巴洛沙韦于2021年在我国上市，此 次华山医院团队开展的研究涵盖近4000例中国患者样本，其中儿童占比44.6%，是基于中国真实世界的 大样本数据，同时也是目前国内针对该药物最大规模的耐药性基线调查。 中国疾控中心流感周报显示玛巴洛沙韦耐药率为"0"，而团队研究发现了0.05%的潜在信号。如何理解两 套监测体系的差异？张文宏指出，两套体系的监测目标不同。疾控中心监测的是"大局"，聚焦是否出现 ...

近年来，网络上一直出现流感抗病毒药物耐药的说法，这一说法是否属实？ 1月23日，智通财经（www.thepaper.cn）记者从复旦大学附属华山医院感染科张文宏团队获悉，其团队 联合国内多家研究机构，完成了一项覆盖近4000例中国患者的真实世界研究。该研究首次全面评估了抗 流感药物"玛巴洛沙韦"自2021年在中国上市后，流感病毒对其敏感性的变化状况。 研究结果显示，在中国大陆，所有已知与玛巴洛沙韦敏感性降低相关的突变总体检出率仅为0.05%。值 得注意的是，在全球其他地区曾有报道的标志性耐药突变I38T，在本研究中未被检测到。这表明，尽管 I38T是明确的耐药性突变位点，但由于其显著降低的病毒适应性，该突变株在自然传播中不具备竞争优 势。 这也是中国首个针对玛巴洛沙韦耐药性的基础研究成果，填补了国内该领域基础研究的空白。同时，研 究结果与中国疾病预防控制中心流感周报中玛巴洛沙韦耐药率为0的监测结果形成呼应，进一步验证了 该药物在国内临床应用的有效性和安全性，更建立了基础研究与临床监测的互补体系，对推动流感防控 科学化、精准化具有重要意义。 值得一提的是，本次研究的样本中，儿童占比44.6%。研究发现，个别突变 ...

Group 1: Core Differences Between Viruses - The two viruses, parainfluenza virus and influenza virus, belong to different virus families, with parainfluenza classified under the Paramyxoviridae family and influenza under the Orthomyxoviridae family [2][3] - Parainfluenza virus has four serotypes and exhibits less mutation capability compared to influenza virus, which has four types (A, B, C, D) and is known for its ability to mutate and create new strains [3] Group 2: Susceptible Populations and Symptoms - Parainfluenza virus primarily affects infants and children, causing acute respiratory infections, particularly lower respiratory tract infections, with symptoms like "barking" cough, hoarseness, stridor, and difficulty breathing [4] - Influenza virus can affect individuals of all ages, presenting with sudden high fever (39-40°C), chills, headaches, muscle aches, and fatigue, while respiratory symptoms are less pronounced [4] Group 3: Prevention and Treatment - There is no vaccine or specific antiviral treatment for parainfluenza virus; management relies on symptomatic support such as fever reduction and cough relief [5] - Influenza virus has an effective vaccine and antiviral medications like oseltamivir and baloxavir marboxil, which can shorten the duration of illness and alleviate symptoms when administered early [5] Group 4: Daily Protective Measures - Basic protective measures against both viruses include frequent handwashing, avoiding touching the face with unclean hands, wearing masks in crowded or poorly ventilated areas, ensuring good indoor ventilation, and maintaining a healthy lifestyle to boost immunity [6][7][8][9][10]

Core Viewpoint - The article discusses the extensive length and complexity of drug instruction leaflets, highlighting the challenges faced by patients in understanding them and the implications for pharmaceutical companies and healthcare professionals [2][5][12]. Group 1: Length and Complexity of Instruction Leaflets - Roche's Marbofloxacin has an instruction leaflet that is 60 centimeters long, with the longest in China reaching 1 meter [2][12]. - The instruction leaflets for some drugs, like Merck's Pembrolizumab, can cover an area of approximately 2 square meters, containing extensive information due to multiple indications and clinical trial data [6][12]. - The complexity of these leaflets often leads to confusion among patients, with some expressing that the adverse effects listed seem more daunting than the illness itself [5][16]. Group 2: Regulatory and Legal Framework - The content and format of drug instruction leaflets are governed by the 2006 National Drug Instruction and Label Management Regulations, which require comprehensive safety and efficacy data [8][12]. - The National Medical Products Administration (NMPA) has established guidelines that dictate the inclusion of 26 essential items in drug leaflets, such as indications, dosage, adverse reactions, and contraindications [8][12]. Group 3: Professional Perspective - Healthcare professionals emphasize that detailed instruction leaflets are beneficial for ensuring patient safety and informed prescribing practices [11][12]. - The length of a leaflet often correlates with the thoroughness of the drug's research, which can help healthcare providers make informed decisions [11][12]. Group 4: Patient Accessibility and Adaptation - There is a growing concern regarding the readability of instruction leaflets, particularly for elderly patients, prompting initiatives for larger print and simplified versions [17][18]. - Some pharmaceutical companies are exploring the use of QR codes to provide electronic versions of leaflets that can be easily accessed and read [18][19].

Core Viewpoint - The article discusses the issue of excessively long medication instruction leaflets, highlighting the confusion and frustration experienced by patients due to the complexity and size of these documents [2][5]. Group 1: Medication Instruction Leaflets - The instruction leaflet for Roche's Marbofloxacin is noted to be 60 centimeters long, with the longest instruction leaflet for any Roche drug in China reaching 1 meter [2]. - A patient expressed that the instruction leaflets are often overwhelming, with one stating that the information on adverse reactions is more daunting than the illness itself [5]. - The instruction leaflets are primarily designed for healthcare professionals, and a higher volume of information typically indicates more thorough scientific research behind the medication [5]. Group 2: Specific Examples of Instruction Leaflets - The longest instruction leaflet encountered by a pharmacy professional is for Merck's Pembrolizumab (commonly known as "K drug"), which totals approximately 2 square meters when unfolded [5][6]. - The instruction leaflet for "K drug" includes 12 cancer types and 19 indications, necessitating the presentation of over 70 charts due to the complexity of treatment protocols and patient-specific factors [6].

Core Viewpoint - The article highlights three major misconceptions regarding flu medication, emphasizing the importance of proper usage of antiviral drugs and the risks associated with incorrect medication practices [1]. Group 1: Misconceptions about Flu Medication - The first misconception is the use of antibiotics for fever, as flu is caused by a virus and antibiotics are ineffective against viruses [1]. - The second misconception is stopping antiviral medication once symptoms improve; completing the full course is necessary to effectively suppress the virus [1]. - The third misconception involves combining multiple medications, which can lead to overdose, particularly with acetaminophen-containing cold medications [1]. Group 2: Antiviral Medication Insights - Antiviral drugs like Oseltamivir and Baloxavir Marboxil work by inhibiting viral replication rather than directly killing the virus [1]. - The article stresses that the first 48 hours after symptom onset is the critical window for antiviral treatment, where early administration is more beneficial than higher doses later on [1].

Core Viewpoint - The article emphasizes the importance of distinguishing between influenza and the common cold, highlighting the differences in symptoms, causative viruses, and appropriate treatments to avoid mismanagement of the illnesses [2][3]. Group 1: Differences Between Influenza and Common Cold - Influenza is caused by influenza viruses (type A and B) and is highly contagious, while the common cold is primarily caused by rhinoviruses and coronaviruses, which are less contagious [3]. - Symptoms of influenza typically include high fever (39-40 degrees Celsius), muscle aches, and severe fatigue, whereas common cold symptoms are milder, often involving nasal congestion, runny nose, and low-grade fever [3]. - Treatment approaches differ: antiviral medications are effective for influenza and can prevent severe illness, while common cold treatment focuses on symptom relief, with antiviral drugs being ineffective [3]. Group 2: Common Medication Misconceptions - Misuse of antibiotics for fever is a common mistake; antibiotics target bacteria, not viruses, and their misuse can lead to antibiotic resistance, posing future health risks [4]. - Stopping antiviral medication prematurely can allow the virus to persist, increasing the risk of recurrence and potential resistance; for instance, oseltamivir should be taken for a full five-day course [4]. - Combining multiple medications can be dangerous; for example, taking both combination cold medications and additional fever reducers can lead to overdose, stressing the liver and kidneys [4].